The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 31, 2026
Filed:
Apr. 07, 2023
Applicant:
Eikonizo Therapeutics, Inc., Cambridge, MA (US);
Inventors:
Florence Fevrier Wagner, Ashland, MA (US);
Thomas Edward Richardson, Cary, NC (US);
Assignee:
Eikonizo Therapeutics, Inc., Cambridge, MA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 413/04 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); A61K 31/4709 (2006.01); A61K 31/4725 (2006.01); A61K 31/498 (2006.01); A61K 31/4985 (2006.01); A61K 31/501 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/5386 (2006.01); C07D 413/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 498/04 (2006.01); C07D 498/08 (2006.01);
U.S. Cl.
CPC ...
C07D 413/04 (2013.01); A61K 31/4439 (2013.01); A61K 31/444 (2013.01); A61K 31/4709 (2013.01); A61K 31/4725 (2013.01); A61K 31/498 (2013.01); A61K 31/4985 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/5386 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 498/04 (2013.01); C07D 498/08 (2013.01);
Abstract
Provided herein are compounds that selectively inhibit HDAC6, a protein whose activity is associated with a variety of diseases (e.g., cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HDAC6-related diseases and disorders (e.g., Alzheimer's disease, cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.